Lower urinary tract dysfunction in the neurological patient: Clinical assessment and management

The Lancet Neurology

Volumn 14, Issue 7, 2015, Pages 720-732

  Panicker, Jalesh N ^a   Fowler, Clare J ^a   Kessler, Thomas M ^b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BOTULINUM TOXIN; DESMOPRESSIN; MUSCARINIC RECEPTOR BLOCKING AGENT;

ANAMNESIS; BLADDER CAPACITY; BLADDER EMPTYING; BLADDER FILLING; BLADDER SPHINCTER; CAUDA EQUINA SYNDROME; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CYSTOSCOPY; DEMENTIA; DEMYELINATING DISEASE; ECHOGRAPHY; END STAGE RENAL DISEASE; FOLLOW UP; FOWLER'S SYNDROME; HUMAN; HYDRONEPHROSIS; INTERMITTENT CATHETERIZATION; LOWER URINARY TRACT SYMPTOM; MICTURITION; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NEUROMODULATION; NEUROPHYSIOLOGY; OVERACTIVE BLADDER; PERIPHERAL NEUROPATHY; PHYSICAL EXAMINATION; PHYSIOTHERAPY; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SHY DRAGER SYNDROME; SPINAL CORD INJURY; SPINAL DYSRAPHISM; URODYNAMICS; UROFLOWMETRY; ADULT; CASE REPORT; COMPLICATION; DISEASE MANAGEMENT; FEMALE; HUMANS; INNERVATION; NERVOUS SYSTEM DISEASES; PHYSIOPATHOLOGY; SPINAL CORD INJURIES; THORACIC VERTEBRAE; URINARY TRACT; UROLOGIC DISEASES;

ADULT; DISEASE MANAGEMENT; FEMALE; HUMANS; MULTIPLE SCLEROSIS; NERVOUS SYSTEM DISEASES; SPINAL CORD INJURIES; THORACIC VERTEBRAE; URINARY TRACT; UROLOGIC DISEASES;

EID: 84930535814     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(15)00070-8     Document Type: Review

References (111)

1. Fowler CJ, Griffiths D, de Groat WC The neural control of micturition. Nat Rev Neurosci 2008, 9:453-466.
2. Fowler CJ Integrated control of lower urinary tract-clinical perspective. Br J Pharmacol 2006, 147(suppl 2):S14-S24.
3. Griffiths DJ The pontine micturition centres. Scand J Urol Nephrol Suppl 2002, 210:21-26.
4. Michels L, Blok BF, Gregorini F, et al. Supraspinal control of urine storage and micturition in men-an fMRI study. Cereb Cortex 2014, published online June 26. 10.1093/cercor/bhu140.
5. Kuhtz-Buschbeck JP, van der Horst C, Pott C, et al. Cortical representation of the urge to void: a functional magnetic resonance imaging study. J Urol 2005, 174:1477-1481.
6. Kuhtz-Buschbeck JP, Gilster R, van der Horst C, et al. Control of bladder sensations: an fMRI study of brain activity and effective connectivity. Neuroimage 2009, 47:18-27.
7. Griffiths D, Derbyshire S, Stenger A, et al. Brain control of normal and overactive bladder. J Urol 2005, 174:1862-1867.
8. Panicker JN, de Sèze M, Fowler CJ Rehabilitation in practice: neurogenic lower urinary tract dysfunction and its management. Clin Rehabil 2010, 24:579-589.
9. de Groat WC, Kawatani M, Hisamitsu T, et al. Mechanisms underlying the recovery of urinary bladder function following spinal cord injury. J Auton Nerv Syst 1990, 30(suppl):S71-S77.
10. McGuire EJ, Woodside JR, Borden TA, et al. Prognostic value of urodynamic testing in myelodysplastic patients. J Urol 1981, 126:205-209.
11. Lawrenson R, Wyndaele JJ, Vlachonikolis I, et al. Renal failure in patients with neurogenic lower urinary tract dysfunction. Neuroepidemiology 2001, 20:138-143.
12. Castel-Lacanal E, Game X, Clanet M, et al. Urinary complications and risk factors in symptomatic multiple sclerosis patients. Study of a cohort of 328 patients. Neurourol Urodyn 2015, 34:32-36.
13. Drake MJ, Apostolidis A, Emmanuel A, et al. Committee 10: Neurologic urinary and faecal incontinence. In: Abrams P, Cardozo L, Khoury S, et al, eds. Incontinence, 5th edn. Paris, France; 2013: 827-1000.
14. Urinary incontinence in neurological disease (CG148) National Institute for Health and Care Excellence, (accessed May 4, 2015). https://www.nice.org.uk/guidance/cg148.
15. Sakakibara R, Kanda T, Sekido T, et al. Mechanism of bladder dysfunction in idiopathic normal pressure hydrocephalus. Neurourol Urodyn 2008, 27:507-510.
16. Ransmayr GN, Holliger S, Schletterer K, et al. Lower urinary tract symptoms in dementia with Lewy bodies, Parkinson disease, and Alzheimer disease. Neurology 2008, 70:299-303.
17. Sink KM, Thomas J, Xu H, et al. Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. J Am Geriatr Soc 2008, 56:847-853.
18. Han KS, Heo SH, Lee SJ, et al. Comparison of urodynamics between ischemic and hemorrhagic stroke patients; can we suggest the category of urinary dysfunction in patients with cerebrovascular accident according to type of stroke?. Neurourol Urodyn 2010, 29:387-390.
19. Wade DT, Hewer RL Outlook after an acute stroke: urinary incontinence and loss of consciousness compared in 532 patients. Q J Med 1985, 56:601-608.
20. Kuchel GA, Moscufo N, Guttmann CR, et al. Localization of brain white matter hyperintensities and urinary incontinence in community-dwelling older adults. J Gerontol A Biol Sci Med Sci 2009, 64:902-909.
21. Tadic SD, Griffiths D, Murrin A, et al. Brain activity during bladder filling is related to white matter structural changes in older women with urinary incontinence. Neuroimage 2010, 51:1294-1302.
22. Sakakibara R, Hattori T, Yasuda K, et al. Micturitional disturbance after acute hemispheric stroke: analysis of the lesion site by CT and MRI. J Neurol Sci 1996, 137:47-56.
23. Uchiyama T, Sakakibara R, Yamamoto T, et al. Urinary dysfunction in early and untreated Parkinson's disease. J Neurol Neurosurg Psychiatry 2011, 82:1382-1386.
24. Sakakibara R, Uchiyama T, Yamanishi T, et al. Genitourinary dysfunction in Parkinson's disease. Mov Disord 2010, 25:2-12.
25. Sakakibara R, Hattori T, Uchiyama T, et al. Videourodynamic and sphincter motor unit potential analyses in Parkinson's disease and multiple system atrophy. J Neurol Neurosurg Psychiatry 2001, 71:600-606.
26. de Seze M, Ruffion A, Denys P, et al. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler 2007, 13:915-928.
27. Panicker JN, Nagaraja D, Kovoor JM, et al. Descriptive study of acute disseminated encephalomyelitis and evaluation of functional outcome predictors. J Postgrad Med 2010, 56:12-16.
28. Schöps TF, Schneider MP, Steffen F, Ineichen BV, Mehnert U, Kessler TM Neurogenic lower urinary tract dysfunction (NLUTD) in patients with spinal cord injury: long-term urodynamic findings. BJU Int 2015, 115(suppl 6):33-38.
29. Blok B, Pannek J, Castro-Diaz D, et al. Guidelines on Neuro-Urology. European Association of Urology (accessed May 4, 2015). http://uroweb.org/wp-content/uploads/21-Neuro-Urology_LR2.pdf.
30. Krassioukov A, Biering-Sorensen F, Donovan W, et al. International standards to document remaining autonomic function after spinal cord injury. J Spinal Cord Med 2012, 35:201-210.
31. Kessler TM, Lackner J, Kiss G, Rehder P, Madersbacher H Predictive value of initial urodynamic pattern on urinary continence in patients with myelomeningocele. Neurourol Urodynam 2006, 25:361-367.
32. Veenboer PW, de Kort LM, Chrzan RJ, de Jong TP Urinary considerations for adult patients with spinal dysraphism. Nat Rev Urol 2015, published online May 12. 10.1038/nrurol.2015.99.
33. Podnar S, Fowler C Pelvic organ dysfunction following cauda equina damage. Pelvic organ dysfunction in neurological disease: clinical management and rehabilitation 2010, 266-277. Cambridge University Press, Cambridge. C. Fowler, J. Panicker, A. Emmanuel (Eds.).
34. Panicker JN, Game X, Khan S, et al. The possible role of opiates in women with chronic urinary retention: observations from a prospective clinical study. J Urol 2012, 188:480-484.
35. Panicker J, DasGupta R, Elneil S, et al. Urinary retention. Pelvic organ dysfunction in neurological disease: clinical management and rehabilitation 2010, 293-306. Cambridge University Press, Cambridge. C. Fowler, J. Panicker, A. Emmanuel (Eds.).
36. Datta SN, Chaliha C, Singh A, et al. Sacral neurostimulation for urinary retention: 10-year experience from one UK centre. BJU Int 2008, 101:192-196.
37. Osman NI, Chapple CR Fowler's syndrome-a cause of unexplained urinary retention in young women?. Nat Rev Urol 2014, 11:87-98.
38. Kessler TM Diagnosis of urinary incontinence. JAMA 2008, 300:283.
39. Labat JJ, Riant T, Robert R, et al. Diagnostic criteria for pudendal neuralgia by pudendal nerve entrapment (Nantes criteria). Neurourol Urodyn 2008, 27:306-310.
40. Brown DL Atlas of regional anesthesia 2006, Saunders (Elsevier), Philadelphia. 3rd edn.
41. Gray's anatomy 2008, Churchill Livingstone (Elsevier). 40th edn. S. Standring (Ed.).
42. Fowler CJ, Panicker JN, Drake M, et al. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009, 80:470-477.
43. Podnar S, Trsinar B, Vodusek DB Bladder dysfunction in patients with cauda equina lesions. Neurourol Urodyn 2006, 25:23-31.
44. Palace J, Chandiramani VA, Fowler CJ Value of sphincter EMG in the diagnosis of multiple system atrophy. Muscle Nerve 1997, 20:1396-1403.
45. Wallace SA, Roe B, Williams K, et al. Bladder training for urinary incontinence in adults. Cochrane Database Syst Rev 2004, 1. CD001308.
46. Eustice S, Roe B, Paterson J Prompted voiding for the management of urinary incontinence in adults. Cochrane Database Syst Rev 2000, 2. CD002113.
47. Ostaszkiewicz J, Johnston L, Roe B Timed voiding for the management of urinary incontinence in adults. Cochrane Database Syst Rev 2004, 1. CD002802.
48. De Ridder D, Vermeulen C, Ketelaer P, et al. Pelvic floor rehabilitation in multiple sclerosis. Acta Neurol Belg 1999, 99:61-64.
49. McClurg D, Ashe RG, Marshall K, et al. Comparison of pelvic floor muscle training, electromyography biofeedback, and neuromuscular electrical stimulation for bladder dysfunction in people with multiple sclerosis: a randomized pilot study. Neurourol Urodyn 2006, 25:337-348.
50. Gajewski JB, Awad SA Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia. J Urol 1986, 135:966-968.
51. Stohrer M, Murtz G, Kramer G, et al. Propiverine compared to oxybutynin in neurogenic detrusor overactivity-results of a randomized, double-blind, multicenter clinical study. Eur Urol 2007, 51:235-242.
52. van Rey F, Heesakkers J Solifenacin in multiple sclerosis patients with overactive bladder: a prospective study. Adv Urol 2011, 2011:834753.
53. Ethans KD, Nance PW, Bard RJ, et al. Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. J Spinal Cord Med 2004, 27:214-218.
54. Mazo EB, Babanina GA Trospium chloride (spasmex) in the treatment of lower urinary tract symptoms in patients with neurogenic hyperactive urinary bladder caused by vertebrogenic lesions. Urologiia 2007, 3:15-19. [in Russian].
55. Davis TP, Sanchez-Covarubias L, Tome ME P-glycoprotein trafficking as a therapeutic target to optimize CNS drug delivery. Adv Pharmacol 2014, 71:25-44.
56. Chancellor MB, Staskin DR, Kay GG, et al. Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. Drugs Aging 2012, 29:259-273.
57. Wagg A, Verdejo C, Molander U Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder. Int J Clin Pract 2010, 64:1279-1286.
58. Madhuvrata P, Singh M, Hasafa Z, et al. Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis. Eur Urol 2012, 62:816-830.
59. Buser N, Ivic S, Kessler TM, et al. Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. Eur Urol 2012, 62:1040-1060.
60. Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med 2015, 175:401-407.
61. Isik AT, Celik T, Bozoglu E, et al. Trospium and cognition in patients with late onset Alzheimer disease. J Nutr Health Aging 2009, 13:672-676.
62. Bosma R, Wynia K, Havlikova E, et al. Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis. Acta Neurol Scand 2005, 112:1-5.
63. Chapple CR, Cardozo L, Nitti VW, et al. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn 2014, 33:17-30.
64. Bartley J, Gilleran J, Peters K Neuromodulation for overactive bladder. Nat Rev Urol 2013, 10:513-521.
65. Xiao Z, Rogers MJ, Shen B, et al. Somatic modulation of spinal reflex bladder activity mediated by nociceptive bladder afferent nerve fibers in cats. Am J Physiol Renal Physiol 2014, 307:F673-F679.
66. Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol 2010, 183:1438-1443.
67. Kabay SC, Kabay S, Yucel M, et al. Acute urodynamic effects of percutaneous posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with Parkinson's disease. Neurourol Urodyn 2009, 28:62-67.
68. Kabay S, Kabay SC, Yucel M, et al. The clinical and urodynamic results of a 3-month percutaneous posterior tibial nerve stimulation treatment in patients with multiple sclerosis-related neurogenic bladder dysfunction. Neurourol Urodyn 2009, 28:964-968.
69. Gobbi C, Digesu GA, Khullar V, et al. Percutaneous posterior tibial nerve stimulation as an effective treatment of refractory lower urinary tract symptoms in patients with multiple sclerosis: preliminary data from a multicentre, prospective, open label trial. Mult Scler 2011, 17:1514-1519.
70. de Seze M, Raibaut P, Gallien P, et al. Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: results of a multicenter prospective study. Neurourol Urodyn 2011, 30:306-311.
71. Monteiro ES, de Carvalho LB, Fukujima MM, et al. Electrical stimulation of the posterior tibialis nerve improves symptoms of poststroke neurogenic overactive bladder in men: a randomized controlled trial. Urology 2014, 84:509-514.
72. Wöllner J, Hampel C, Kessler TM Surgery illustrated-surgical atlas sacral neuromodulation. BJU Int 2012, 110:146-159.
73. Knüpfer SC, Liechti MD, Mordasini L, et al. Protocol for a randomized, placebo-controlled, double-blind clinical trial investigating sacral neuromodulation for neurogenic lower urinary tract dysfunction. BMC Urol 2014, 14:65.
74. Kessler TM, La Framboise D, Trelle S, et al. Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis. Eur Urol 2010, 58:865-874.
75. Sievert KD, Amend B, Gakis G, et al. Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury. Ann Neurol 2010, 67:74-84.
76. Amend B, Matzel KE, Abrams P, et al. How does neuromodulation work. Neurourol Urodyn 2011, 30:762-765.
77. Wyndaele JJ, Michielsen D, Van Dromme S Influence of sacral neuromodulation on electrosensation of the lower urinary tract. J Urol 2000, 163:221-224.
78. Braun PM, Baezner H, Seif C, et al. Alterations of cortical electrical activity in patients with sacral neuromodulator. Eur Urol 2002, 41:562-566.
79. Malaguti S, Spinelli M, Giardiello G, et al. Neurophysiological evidence may predict the outcome of sacral neuromodulation. J Urol 2003, 170:2323-2326.
80. Fowler CJ, Swinn MJ, Goodwin RJ, et al. Studies of the latency of pelvic floor contraction during peripheral nerve evaluation show that the muscle response is reflexly mediated. J Urol 2000, 163:881-883.
81. Schurch B, Reilly I, Reitz A, et al. Electrophysiological recordings during the peripheral nerve evaluation (PNE) test in complete spinal cord injury patients. World J Urol 2003, 20:319-322.
82. Schurch B, Stohrer M, Kramer G, et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000, 164:692-697.
83. Schurch B, Schmid DM, Stohrer M Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 2000, 342:665.
84. Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 2011, 60:742-750.
85. Ginsberg D, Gousse A, Keppenne V, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol 2012, 187:2131-2139.
86. Mangera A, Apostolidis A, Andersson KE, et al. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur Urol 2014, 65:981-990.
87. Sussman D, Patel V, Del Popolo G, et al. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. Neurourol Urodyn 2013, 32:242-249.
88. Chancellor MB, Patel V, Leng WW, et al. OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity. Neurology 2013, 81:841-848.
89. Rovner E, Dmochowski R, Chapple C, et al. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity. Neurourol Urodyn 2013, 32:1109-1115.
90. Wöllner J, Kessler TM Botulinum toxin injections into the detrusor. BJU Int 2011, 108:1528-1537.
91. Giannantoni A, Mearini E, Del Zingaro M, et al. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Eur Urol 2009, 55:705-711.
92. Kennelly M, Dmochowski R, Ethans K, et al. Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis. Urology 2013, 81:491-497.
93. Carlson JJ, Hansen RN, Dmochowski RR, et al. Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States. Clin Ther 2013, 35:414-424.
94. Seth JH, Haslam C, Panicker JN Ensuring patient adherence to clean intermittent self-catheterization. Patient Prefer Adherence 2014, 8:191-198.
95. Prasad RS, Smith SJ, Wright H Lower abdominal pressure versus external bladder stimulation to aid bladder emptying in multiple sclerosis: a randomized controlled study. Clin Rehabil 2003, 17:42-47.
96. Naumann M, So Y, Argoff CE, et al. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, 70:1707-1714.
97. Averbeck MA, Madersbacher H Follow-up of the neuro-urological patient: a systematic review. BJU Int 2015, 115(suppl 6):39-46.
98. Gregorini F, Wollner J, Schubert M, et al. Sensory evoked potentials of the human lower urinary tract. J Urol 2013, 189:2179-2185.
99. Leitner L, Walter M, Freund P, et al. Protocol for a prospective magnetic resonance imaging study on supraspinal lower urinary tract control in healthy subjects and spinal cord injury patients undergoing intradetrusor onabotulinumtoxinA injections for treating neurogenic detrusor overactivity. BMC Urol 2014, 14:68.
100. Giannarini G, Kessler TM, Roth B, et al. Functional multiparametric magnetic resonance imaging of the kidneys using blood oxygen level dependent and diffusion-weighted sequences. J Urol 2014, 192:434-439.
101. Thoeny HC, Binser T, Roth B, et al. Noninvasive assessment of acute ureteral obstruction with diffusion-weighted MR imaging: a prospective study. Radiology 2009, 252:721-728.
102. Thoeny HC, Kessler TM, Simon-Zoula S, et al. Renal oxygenation changes during acute unilateral ureteral obstruction: assessment with blood oxygen level-dependent MR imaging-initial experience. Radiology 2008, 247:754-761.
103. Drake MJ, Mills IW, Noble JG Melatonin pharmacotherapy for nocturia in men with benign prostatic enlargement. J Urol 2004, 171:1199-1202.
104. Seif C, Herzog J, van der Horst C, et al. Effect of subthalamic deep brain stimulation on the function of the urinary bladder. Ann Neurol 2004, 55:118-120.
105. Herzog J, Weiss PH, Assmus A, et al. Subthalamic stimulation modulates cortical control of urinary bladder in Parkinson's disease. Brain 2006, 129:3366-3375.
106. Herzog J, Weiss PH, Assmus A, et al. Improved sensory gating of urinary bladder afferents in Parkinson's disease following subthalamic stimulation. Brain 2008, 131:132-145.
107. Mordasini L, Kessler TM, Kiss B, et al. Bladder function in patients with dystonia undergoing deep brain stimulation. Parkinsonism Relat Disord 2014, 20:1015-1017.
108. Kessler TM, Burkhard FC, Z'Brun S, et al. Effect of thalamic deep brain stimulation on lower urinary tract function. Eur Urol 2008, 53:607-612.
109. Atala A, Bauer SB, Soker S, et al. Tissue-engineered autologous bladders for patients needing cystoplasty. Lancet 2006, 367:1241-1246.
110. Liebscher T, Schnell L, Schnell D, et al. Nogo-A antibody improves regeneration and locomotion of spinal cord-injured rats. Ann Neurol 2005, 58:706-719.
111. Schneider MP, Schwab ME, Kessler TM Anti-Nogo-A antibody: a treatment option for neurogenic lower urinary tract dysfunction?. BJU Int 2015, 115(suppl 6):16-17.